Physician profile
Arlene Roman
NPI 1124131198
$3,477.86
in general payments reported to CMS, 2019-2025
17 companies · $1,178 in 2025
The $1,178 reported for 2025 was more than what 83% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $401 · 2020: $225 · 2021: $67.28 · 2022: $32.85 · 2023: $455 · 2024: $1,119 · 2025: $1,178.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,747 · Education: $5.14.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,746.70 |
| Education | $5.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,047.64 | 2020-2025 | Caplyta |
| Abbvie INC. | $468.20 | 2024-2025 | |
| Vanda Pharmaceuticals INC. | $393.94 | 2019-2025 | Fanapt |
| Otsuka America Pharmaceutical, INC. | $383.54 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Lundbeck LLC | $299.54 | 2019-2025 | Rexulti |
| Sunovion Pharmaceuticals INC. | $156.74 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $143.10 | 2025 | Cobenfy |
| Teva Pharmaceuticals USA, INC. | $140.29 | 2025 | Uzedy, Austedo Xr |
| Neurocrine Biosciences, INC. | $138.58 | 2019-2025 | Ingrezza |
| Janssen Pharmaceuticals, INC | $56.87 | 2019-2025 | Invega Sustenna |
| Alkermes, INC. | $53.81 | 2023 | Aristada, Lybalvi |
| Axsome Therapeutics, INC. | $47.67 | 2022-2023 | Auvelity |
| Ironshore Pharmaceuticals INC. | $35.78 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $35.23 | 2025 | Trintellix |
| Allergan, INC. | $32.12 | 2019-2020 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neos Therapeutics, Lp | $29.44 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $15.37 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arlene Roman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.